Insights from a CSL-sponsored Harris Poll survey*
*Online survey of 104 US adults with PI who ever received IVIg (n=65), SCIg in glass vials (n=65), and/or SCIg in prefilled syringes (n=33).
View the patients below to learn how Hizentra addresses lifestyle burdens associated with IVIg
SaraAge 33 | 165 lb (74 kg)†
Why Hizentra?
Dose: 10 g/50 mL, every 10 days | Infusion sites: 2
Time per infusion‡: ~1 hour
AnthonyAge 17 | 180 lb (82 kg)†
Why Hizentra?
Dose: 6 g/30 mL, twice a week | Infusion sites: 2
Time per infusion‡: ~38 minutes
View the patients below to learn how Hizentra addresses clinical challenges associated with IVIg
MarieAge 65 | 146 lb (66 kg)†
Why Hizentra?
Dose: 16 g/80 mL, once every 2 weeks | Infusion sites: 4
Time per infusion‡: ~48 minutes
IanAge 46 | 200 lb (91 kg)†
Why Hizentra?
Dose: 14 g/70 mL, once a week | Infusion sites: 3
Time per infusion‡: ~1 hour
†Rate of infusion and number of infusion sites in these hypothetical case studies are based on recommended rate and volume per site of subsequent infusions.
Photos and case studies do not depict actual patients.
‡Infusion time may be shorter or longer depending on the dose and frequency prescribed.
Explore tools and information to help you tailor treatment to individual patient needs
Dosing calculatorKeep your patients on track with Hizentra and engaged throughout their treatment journey
Online scheduleSee how Hizentra offers personalized therapy and greater freedom for your patients with PI
Explore the benefitsExplore volumes, rates, and other information to help your patients self-administer Hizentra
Administration guidance
